Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139341 | 0.81 | MAPK1 (0.47) | PNMTTAAR1SIGMAR1MAPK1TDP1 | |
| SCHEMBL30387398 | 0.81 | MAPK1 (0.47) | PNMTTAAR1SIGMAR1MAPK1TDP1 | |
| SCHEMBL331135 | 0.80 | MIF (0.48) | MIFTSHR | |
| SCHEMBL1846505 | 0.79 | MIF (0.66) | TAAR1IDO1MIFALDH1A1 | |
| SCHEMBL29542006 | 0.78 | HTR3E (0.54) | PNMTTAAR1IDO1MIFMEN1 | |
| SCHEMBL1851734 | 0.78 | HTR3E (0.54) | PNMTTAAR1IDO1MIFMEN1 | |
| SCHEMBL7414073 | 0.76 | PNMT (0.57) | PNMTTAAR1SIGMAR1IDO1IGF1R | |
| SCHEMBL6804290 | 0.76 | MIF (0.50) | TAAR1MIFCYP1A2MEN1KMT2A | |
| SCHEMBL12305277 | 0.76 | MIF (0.38) | MIF | |
| SCHEMBL29077870 | 0.75 | MIF (0.37) | MIFTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| US-20220363809-A1 | POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-11-17 | — | — | US | disclosed |
| WO-2022179939-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2022-09-01 | — | — | WO | disclosed |
| CN-109280030-B | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3107946-A1 | A POLYISO-UREA | BASF SE (DE) | 2016-12-28 | — | — | EP | disclosed |
| EP-3107945-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015127038-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015127041-A1 | A POLYISO-UREA | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2111443-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | The Procter and Gamble Company (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200363-A1 | Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost | PROECTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | disclosed |
| WO-2008100601-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2008-08-21 | — | — | WO | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ROCK1, ROCK2, RHOA | PNMT 2634/4885TAAR1 3725/4885SIGMAR1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.